The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for primary and metastatic liver tumors. It delivers SD-101, a class C toll-like receptor 9 (TLR9) agonist.
Last week, TriSalus announced plans to go public through a merger with MedTech Acquisition Corp., a special purpose acquisition company (SPAC).
“We are commercializing our TriNav infusion system and developing SD-101 to potentially enable more patients with liver and pancreatic tumors to benefit from immunotherapeutics and the current standard of care,” said Mary Szela, president and CEO of TriSalus.